The direct infection of endothelial cells by coronavirus through angiotensin-converting enzyme 2 and the high concentration of proinflammatory cytokines, such as tumor necrosis factor-α and interleukins, activated by COVID-19 have been considered to play important roles in COVID-19-related coagulopathy [9, 10]. This evidence concerns the gene ACE2 and blood coagulation disease.